SLC5A2 and heart failure: To address this gap, we conducted a systematic review and multidomain meta-analysis of randomized trials evaluating the effects of SGLT2 inhibitors on clinical outcomes, symptoms and health status, functional capacity, and cardiac remodeling in patients with heart failure across the full ejection fraction spectrum.